Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. Severe nausea and vomiting and urate nephropathy were the dose-limiting toxic effects. Therapeutic responses occurred in four of 24 children with acute lymphocytic leukemia and in two of seven with acute nonlymphoblastic leukemia.
D000208:Acute Disease; D058186:Acute Kidney Injury / Q000139:chemically induced; D002648:Child; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004341:Drug Evaluation; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D013872:Thionucleosides / Q000627:therapeutic use* / Q000633:toxicity; D014527:Uric Acid / Q000652:urine; D014839:Vomiting / Q000139:chemically induced
D013872:Thionucleosides; D014527:Uric Acid; C010438:beta-2'-deoxythioguanosine; D003849:Deoxyguanosine